Literature DB >> 19622045

HIV subtype D is associated with dementia, compared with subtype A, in immunosuppressed individuals at risk of cognitive impairment in Kampala, Uganda.

Ned Sacktor1, Noeline Nakasujja, Richard L Skolasky, Mona Rezapour, Kevin Robertson, Seggane Musisi, Elly Katabira, Allan Ronald, David B Clifford, Oliver Laeyendecker, Thomas C Quinn.   

Abstract

BACKGROUND: In the United States, clade B is the predominant human immunodeficiency virus (HIV) subtype, whereas in sub-Saharan Africa, clades A, C, and D are the predominant subtypes. HIV subtype may have an impact on HIV disease progression. The effect of HIV subtype on the risk of dementia has, to our knowledge, not been examined. The objective of this study was to examine the relationship between HIV subtype and the severity of HIV-associated cognitive impairment among individuals initiating antiretroviral therapy in Uganda.
METHODS: Sixty antiretroviral-naive HIV-infected individuals with advanced immunosuppression who were at risk of HIV-associated cognitive impairment underwent neurological, neuropsychological, and functional assessments, and gag and gp41 regions were subtyped. Subtype assignments were generated by sequence analysis using a portion of the gag and gp41 regions.
RESULTS: Thirty-three HIV-infected individuals were infected with subtype A, 2 with subtype C, 9 with subtype D, and 16 with A/D recombinants. Eight (89%) of 9 HIV-infected individuals with subtype D had dementia, compared with 7 (24%) of 33 HIV-infected individuals with subtype A (P = .004).
CONCLUSIONS: These results suggest that, in untreated HIV-infected individuals with advanced immunosuppression who are at risk of developing HIV-associated cognitive impairment, HIV dementia may be more common among patients infected with subtype D virus than among those infected with subtype A virus. These findings provide the first evidence, to our knowledge, to demonstrate that HIV subtypes may have a pathogenetic factor with respect to their capacity to cause cognitive impairment. Additional studies are needed to confirm this observation and to define the mechanism by which subtype D leads to an increased risk of neuropathogenesis.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19622045      PMCID: PMC2941149          DOI: 10.1086/605284

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN: 1058-4838            Impact factor:   9.079


  32 in total

1.  Predominance of HIV type 1 subtype G among commercial sex workers from Kinshasa, Democratic Republic of Congo.

Authors:  C Yang; B Dash; S L Hanna; H S Frances; N Nzilambi; R C Colebunders; M St Louis; T C Quinn; T M Folks; R B Lal
Journal:  AIDS Res Hum Retroviruses       Date:  2001-03-01       Impact factor: 2.205

2.  Analysis of mutations made during active synthesis or extension of mismatched substrates further define the mechanism of HIV-RT mutagenesis.

Authors:  Gwyneth R Liesch; Jeffrey J DeStefano
Journal:  Biochemistry       Date:  2003-05-20       Impact factor: 3.162

3.  Minimal requirements for the human immunodeficiency virus type 1 V3 domain to support the syncytium-inducing phenotype: analysis by single amino acid substitution.

Authors:  J J De Jong; A De Ronde; W Keulen; M Tersmette; J Goudsmit
Journal:  J Virol       Date:  1992-11       Impact factor: 5.103

Review 4.  HIV-1 dynamics in vivo: implications for therapy.

Authors:  Viviana Simon; David D Ho
Journal:  Nat Rev Microbiol       Date:  2003-12       Impact factor: 60.633

5.  Detection of diverse variants of human immunodeficiency virus-1 groups M, N, and O and simian immunodeficiency viruses from chimpanzees by using generic pol and env primer pairs.

Authors:  C Yang; B C Dash; F Simon; G van der Groen; D Pieniazek; F Gao; B H Hahn; R B Lal
Journal:  J Infect Dis       Date:  2000-05-15       Impact factor: 5.226

Review 6.  The AIDS dementia complex.

Authors:  R W Price; B J Brew
Journal:  J Infect Dis       Date:  1988-11       Impact factor: 5.226

7.  Effect of human immunodeficiency virus (HIV) type 1 envelope subtypes A and D on disease progression in a large cohort of HIV-1-positive persons in Uganda.

Authors:  Pontiano Kaleebu; Neil French; Cedric Mahe; David Yirrell; Christine Watera; Fred Lyagoba; Jessica Nakiyingi; Alleluiah Rutebemberwa; Dilys Morgan; Jonathan Weber; Charles Gilks; Jimmy Whitworth
Journal:  J Infect Dis       Date:  2002-04-16       Impact factor: 5.226

8.  WHO Neuropsychiatric AIDS study, cross-sectional phase II. Neuropsychological and neurological findings.

Authors:  M Maj; P Satz; R Janssen; M Zaudig; F Starace; L D'Elia; B Sughondhabirom; M Mussa; D Naber; D Ndetei
Journal:  Arch Gen Psychiatry       Date:  1994-01

9.  Benefits and risks of stavudine therapy for HIV-associated neurologic complications in Uganda.

Authors:  N Sacktor; N Nakasujja; R L Skolasky; K Robertson; S Musisi; A Ronald; E Katabira; D B Clifford
Journal:  Neurology       Date:  2009-01-13       Impact factor: 9.910

10.  Syncytium-inducing and non-syncytium-inducing capacity of human immunodeficiency virus type 1 subtypes other than B: phenotypic and genotypic characteristics. WHO Network for HIV Isolation and Characterization.

Authors:  F De Wolf; E Hogervorst; J Goudsmit; E M Fenyö; H Rübsamen-Waigmann; H Holmes; B Galvao-Castro; E Karita; C Wasi; S D Sempala
Journal:  AIDS Res Hum Retroviruses       Date:  1994-11       Impact factor: 2.205

View more
  64 in total

1.  Improved neuropsychological and neurological functioning across three antiretroviral regimens in diverse resource-limited settings: AIDS Clinical Trials Group study a5199, the International Neurological Study.

Authors:  K Robertson; H Jiang; J Kumwenda; K Supparatpinyo; S Evans; T B Campbell; R Price; S Tripathy; N Kumarasamy; A La Rosa; B Santos; M T Silva; S Montano; C Kanyama; S Faesen; R Murphy; C Hall; C M Marra; C Marcus; B Berzins; R Allen; M Housseinipour; F Amod; I Sanne; J Hakim; A Walawander; A Nair
Journal:  Clin Infect Dis       Date:  2012-06-01       Impact factor: 9.079

2.  Most HIV type 1 non-B infections in the Spanish cohort of antiretroviral treatment-naïve HIV-infected patients (CoRIS) are due to recombinant viruses.

Authors:  Gonzalo Yebra; Miguel de Mulder; Leticia Martín; Carmen Rodríguez; Pablo Labarga; Isabel Viciana; Juan Berenguer; María Remedios Alemán; Juan Antonio Pineda; Federico García; Africa Holguín
Journal:  J Clin Microbiol       Date:  2011-12-07       Impact factor: 5.948

3.  HIV-subtype A is associated with poorer neuropsychological performance compared with subtype D in antiretroviral therapy-naive Ugandan children.

Authors:  Michael J Boivin; Theodore D Ruel; Hannah E Boal; Paul Bangirana; Huyen Cao; Leigh A Eller; Edwin Charlebois; Diane V Havlir; Moses R Kamya; Jane Achan; Carolyne Akello; Joseph K Wong
Journal:  AIDS       Date:  2010-05-15       Impact factor: 4.177

4.  A conserved determinant in the V1 loop of HIV-1 modulates the V3 loop to prime low CD4 use and macrophage infection.

Authors:  Thomas Musich; Paul J Peters; Maria José Duenas-Decamp; Maria Paz Gonzalez-Perez; James Robinson; Susan Zolla-Pazner; Jonathan K Ball; Katherine Luzuriaga; Paul R Clapham
Journal:  J Virol       Date:  2010-12-15       Impact factor: 5.103

5.  Neurocognitive and motor deficits in HIV-infected Ugandan children with high CD4 cell counts.

Authors:  Theodore D Ruel; Michael J Boivin; Hannah E Boal; Paul Bangirana; Edwin Charlebois; Diane V Havlir; Philip J Rosenthal; Grant Dorsey; Jane Achan; Carolyne Akello; Moses R Kamya; Joseph K Wong
Journal:  Clin Infect Dis       Date:  2012-02-04       Impact factor: 9.079

6.  Efficient transmission and persistence of low-frequency SIVmac251 variants in CD8-depleted rhesus macaques with different neuropathology.

Authors:  Samantha L Strickland; Rebecca R Gray; Susanna L Lamers; Tricia H Burdo; Ellen Huenink; David J Nolan; Brian Nowlin; Xavier Alvarez; Cecily C Midkiff; Maureen M Goodenow; Kenneth Williams; Marco Salemi
Journal:  J Gen Virol       Date:  2012-02-01       Impact factor: 3.891

7.  Suicide risk and prevalence of major depressive disorder (MDD) among individuals infected with HIV-1 subtype C versus B in Southern Brazil.

Authors:  Sergio Monteiro de Almeida; Francisco Jaime Barbosa; Rujvi Kamat; Ana Paula de Pereira; Sonia Mara Raboni; Indianara Rotta; Clea Elisa Ribeiro; Mariana Cherner; Ronald J Ellis; Joseph Hampton Atkinson
Journal:  J Neurovirol       Date:  2016-07-18       Impact factor: 2.643

Review 8.  HIV-1 gp120 and drugs of abuse: interactions in the central nervous system.

Authors:  Peter S Silverstein; Ankit Shah; James Weemhoff; Santosh Kumar; D P Singh; Anil Kumar
Journal:  Curr HIV Res       Date:  2012-07       Impact factor: 1.581

9.  Neurocognitive impairment and psychiatric comorbidity in well-controlled human immunodeficiency virus-infected Thais from the 2NN Cohort Study.

Authors:  Wadchara Pumpradit; Jintanat Ananworanich; Sermsak Lolak; Cecilia Shikuma; Robert Paul; Umaporn Siangphoe; Nithima Chaoniti; Peeraporn Kaew-On; Robert Paris; Kiat Ruxrungtham; Victor Valcour
Journal:  J Neurovirol       Date:  2010-02       Impact factor: 2.643

10.  Neruodevelopmental Outcomes in Preschool Children Living With HIV-1 Subtypes A and D in Uganda.

Authors:  Horacio Ruiseñor-Escudero; Alla Sikorskii; Itziar Familiar-Lopez; Deborah Persaud; Carrie Ziemniak; Noeline Nakasujja; Robert Opoka; Michael Boivin
Journal:  Pediatr Infect Dis J       Date:  2018-12       Impact factor: 2.129

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.